$27.12 meals Payment -- AstraZeneca to Dr. Karen Harris

Payment Details

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

AstraZeneca made a $27.12 meals payment to Karen Harris, a Nephrology specialist in City, MO. The payment was associated with Ibrance. A $27.12 meal payment was made by AstraZeneca to Dr. Karen Harris, a Nephrology specialist. The payment was for 'Food and Beverage' related to the drug Ibrance. This payment occurred on February 14, 2025, in Missouri.

Patient Guidance: What This Payment Means for You

This payment represents a meal provided by a pharmaceutical company, which may be related to educational information about a drug. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

For Nephrology specialists, meal payments are common and typically fall within a low to moderate range, with $27.12 being a very modest amount.

Regulatory Context: Sunshine Act Requirements

Payments for meals and beverages are reportable under the Open Payments program if they meet certain thresholds and are not de minimis.

Related Topics

This payment is related to the following healthcare transparency topics:

• meals
• food-and-beverage
• astrazeneca
• ibrance
• nephrology
• physician-payment

Understanding meals Payments

Food and beverage payments cover meals provided to physicians during pharmaceutical sales representative visits, medical conferences, and educational events. While individual meal payments tend to be small (often under $100), research published in JAMA Internal Medicine has shown that even modest meals can be associated with changes in prescribing behavior. Meal payments are the most common type of pharmaceutical payment to physicians.

Frequently Asked Questions About This Payment

What was this $27.12 payment for?

This was a meals payment of $27.12 from AstraZeneca to Karen Harris, categorized as "Food and Beverage". It was associated with Ibrance. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Karen Harris accept pharmaceutical money?

Yes, Karen Harris received this $27.12 payment from AstraZeneca. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Karen Harris's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this meals payment?

A meals payment of $27.12 is generally routine and common in the industry. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Nephrology?

To compare this payment against Nephrology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Nephrology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Karen Harris's relationship with AstraZeneca?

The payment amount is relatively small, suggesting a minor interaction. This $27.12 meals payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Nephrology?

The payment type is 'meals', a common form of non-cash compensation.

What should patients do after learning about this payment?

This payment represents a meal provided by a pharmaceutical company, which may be related to educational information about a drug.

What else should I know about this meals payment?

The specific drug mentioned is Ibrance, indicating a potential focus on oncology or related fields.

Related Reports

• View Dr. Karen Harris's full payment report
• AstraZeneca full spending report
• Browse all Nephrology payments
• Browse all payments in Missouri
• Search for other payments